Bullboard Post History

by Gbathat

Order by:

PMN	Prestigious presentation for Cashman in May? https://patch.com/massachusetts/boston/calendar/event/20200519/750827/protein... February 15, 2020
PMN	RE:RE:ban2401 comparison It is interesting to read all the press about Roche ph3 failure announcement,... February 11, 2020
PMN	RE:RE:ban2401 vs aducanumab and this one as well on the comparative binding assays https://www.bioarctic... February 9, 2020
PMN	RE:ban2401 vs aducanumab meant to include this link in previous post: https://www.bioarctic.se/en/wp... February 9, 2020
PMN	ban2401 vs aducanumab https://clinicaltrials.gov/ct2/show/NCT03887455 interesting presentation... February 8, 2020
PMN	ban2401 comparison one of the questions that had always been bothering me about PMN310 was... February 8, 2020
PMN	January 2020 presentation looks great https://promisneurosciences.com/wp-content/uploads/2020/01/Corporate-Overview... February 1, 2020
PMN	A guy can dream AZ market peak sales estimate: $25B Market share goal: ??? Let's say 20%... February 1, 2020
PMN	IND Is there a revised target date for pmn310 phI trials? Their most recent... January 20, 2020
PMN	insider buying $126K "In connection with the two closings insiders of the Company have... January 1, 2020
PMN	RE:RE:Is it possible? Correction... Amount that biogen market cap went up.... Something like 15B if... December 28, 2019
PMN	RE:Is it possible? Good buying opportunity, keep driving that price down TB. The... December 28, 2019
PMN	RE:RE:RE:Untangling the Beta-Amyloid Oligomers from pg 23 of analyst report: Our discounted cash flow (DCF) model uses a 15... July 4, 2018
PMN	RE:RE:RE:Untangling the Beta-Amyloid Oligomers Here@s Zacks.com description of price target with references to valuation... July 3, 2018
PMN	RE:RE:Untangling the Beta-Amyloid Oligomers I think an analyst price target is typically 12-18 months. The report at... July 3, 2018